默沙东：利普卓®（奥拉帕利）联合阿比特龙和泼尼松或泼尼松龙在华获批用于治疗携带胚系或体细胞BRCA突变的转移性去势抵抗性前列腺癌成人患者

Core Viewpoint - Merck has received approval from the National Medical Products Administration of China for its PARP inhibitor, Lynparza (olaparib), in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) carrying germline or somatic BRCA mutations [1] Group 1 - The approval is specifically for adult patients with mCRPC who have either germline BRCA mutations (gBRCAm) or somatic BRCA mutations (sBRCAm) [1] - This combination therapy represents a significant advancement in the treatment options available for mCRPC patients in China [1] - The collaboration between Merck and AstraZeneca highlights the ongoing efforts to enhance cancer treatment through innovative drug combinations [1]